UNIGE document Scientific Article
previous document  unige:25098  next document
add to browser collection

Levodopa in the treatment of Parkinson's disease: an old drug still going strong

Poewe, Werner
Antonini, Angelo
Zijlmans, Jan Cm
Published in Clinical Interventions in Aging. 2010, vol. 5, p. 229-38
Abstract After more than 40 years of clinical use, levodopa (LD) remains the gold standard of symptomatic efficacy in the drug treatment of Parkinson's disease (PD). Compared with other available dopaminergic therapies, dopamine replacement with LD is associated with the greatest improvement in motor function. Long-term treatment with LD is, however, often complicated by the development of various types of motor response oscillations over the day, as well as drug-induced dyskinesias. Motor fluctuations can be improved by the addition of drugs such as entacapone or monoamine oxidase inhibitors, which extend the half-life of levodopa or dopamine, respectively. However, dyskinesia control still represents a major challenge. As a result, many neurologists have become cautious when prescribing therapy with LD. This review summarizes the available evidence regarding the use of LD to treat PD and will also address the issue of LD delivery as a critical factor for the drug's propensity to induce motor complications.
Keywords AgedAntiparkinson Agents/administration & dosage/adverse effectsDyskinesia, Drug-Induced/etiologyHumansLevodopa/administration & dosage/adverse effectsParkinson Disease/drug therapy
PMID: 20852670
Full text
Article (Published version) (2.2 MB) - public document Free access
Research group Groupe Pierre Burkhard (neurologie) (154)
(ISO format)
POEWE, Werner et al. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. In: Clinical Interventions in Aging, 2010, vol. 5, p. 229-38. https://archive-ouverte.unige.ch/unige:25098

721 hits



Deposited on : 2013-01-08

Export document
Format :
Citation style :